Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oric Pharmaceuticals, Inc. (ORIC : NSDQ)

• Company Description    ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco, United States. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $3.50 Daily Weekly Monthly 20 Day Moving Average: 506,436 shares Shares Outstanding: 39.48 (millions) Market Capitalization: $138.17 (millions) Beta: 2.40 52 Week High: $26.50 52 Week Low: $2.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.79% -1.16% 12 Week -57.93% -54.35% Year To Date -76.19% -71.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 240 E. GRAND AVE. 2ND FLOOR - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-388-5600 fax: - investors@oricpharma.com http://www.oricpharma.com

• General Corporate Information    Officers Jacob M. Chacko - Chief Executive Officer and President Richard Heyman - Chairman Dominic Piscitelli - Chief Financial Officer Mardi Dier - Director Steven Hoerter - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68622P109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 39.48 Most Recent Split Date: (:1) Beta: 2.40 Market Capitalization: $138.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -31.11% vs. Previous Quarter: -1.72% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -31.74 12/31/21 - -28.65 09/30/21 - -30.19 ROA 03/31/22 - -29.53 12/31/21 - -27.03 09/30/21 - -28.90 Current Ratio 03/31/22 - 20.23 12/31/21 - 15.88 09/30/21 - 24.60 Quick Ratio 03/31/22 - 20.23 12/31/21 - 15.87 09/30/21 - 24.60 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 6.41 12/31/21 - 6.93 09/30/21 - 7.41 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©